Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Recruiting now · Phase 4
Conditions studied: ADHD, Attention Deficit Hyperactivity Disorder
In brief
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Key facts
- Study ID
- NCT03781752
- Run by
- Icahn School of Medicine at Mount Sinai
- People needed
- 500
- Starts
- 2018-03-04
- Expected to finish
- 2025-08-01
- Last updated by the study team
- 2024-08-09
Who can join
Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Youth ages 6-17 years with ADHD as a primary diagnosis
You may not qualify if…
- Participants that do not have ADHD as a primary diagnosis
- Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians
- Participants that are smokers or, are pregnant
Where it is running
- University of Florida — Gainesville, Florida, United States (enrolling)
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
- Seattle Children's Hospital — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.